Please login to the form below

Not currently logged in
Email:
Password:

Patheon hires Covance's Michael Lehmann for global pharma role

He joins the contract development and manufacturing company as president of global pharmaceutical development services

Michael Lehmann has left contract research organisation Covance to join Patheon as president of global pharmaceutical development services.

Patheon, which provides both contract development and manufacturing services to pharma companies, said that Lehmann's appointment will help drive the company's growth as it continues to transform its business amid varying marketing conditions.

This includes the company's recent acquisition of speciality pharma firm Banner Pharmacaps for $255m.

"I am pleased to be welcoming Mike and getting him quickly integrated with Patheon's leadership team," stated James Mullen, Patheon's CEO.

"He is a highly accomplished senior executive with a proven track record in the healthcare, life sciences and drug development sectors.”

Lehmann's most recent role was corporate senior VP and general manager of the global early development business of the contract research organisation (CRO) Covance.

During his time in this role, he helped Covance secure deals with both Lilly and Sanofi.

Prior to joining Covance, Lehmann spent 17 years at GE Healthcare in several senior roles, including general manager of multivendor services.

2nd November 2012

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics